Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > LATEST
LATEST
-
REGULATORY Japan’s HIV, AIDS Cases Rebound in 2023 after COVID
March 28, 2024
-
BUSINESS Sosei Group to Be Renamed “Nxera Pharma” from April
March 28, 2024
-
REGULATORY Japan Govt Launches Panel to Respond to Red Yeast Rice Issue
March 28, 2024
-
BUSINESS Abilify Maintena Gets EU Nod as 1st 2-Month Injectable for Schizophrenia
March 28, 2024
-
BUSINESS AstraZeneca’s Japan Sales Up 8.2% in 2023 Despite Nexium Patent Cliff
March 27, 2024
-
REGULATORY Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
March 27, 2024
-
BUSINESS Incyte Appoints Eiji Ueda as Japan Chief
March 27, 2024
-
REGULATORY PMDA Chief Fujiwara to Remain Skipper for Another Term
March 27, 2024
-
BUSINESS SanBio to Submit Additional Data to Obtain Approval for Lead Cell Therapy
March 27, 2024
-
BUSINESS One Dead after Taking Kobayashi’s Red Yeast Rice Pills
March 27, 2024
-
BUSINESS Kobayashi’s Beni Koji Health Damage Reports Trigger Knock-On Recalls
March 27, 2024
-
REGULATORY PMDA to Build Shared Database of GMP Inspection Reports
March 26, 2024
-
BUSINESS CureApp Files Alcoholism Therapy App in Japan
March 26, 2024
-
REGULATORY Japan Shelves Decision on SanBio’s Lead Cell Therapy on Quality Concerns
March 26, 2024
-
ORGANIZATION Backed by 12 Pharmas, US Nonprofit’s Cloud Platform Now Up and Running to Streamline Regulatory Submissions
March 26, 2024
-
BUSINESS Eisai Settles Lenvima Patent Suit with Sun Pharma
March 26, 2024
-
BUSINESS EMA Panel Gives Go-Ahead for Xtandi Use in Earlier Setting: Astellas
March 26, 2024
-
BUSINESS Boehringer’s Brigimadlin Earns Sakigake Designation
March 26, 2024
-
BUSINESS Daiichi Sankyo Files MMR Vaccine in Japan
March 26, 2024
-
BUSINESS Hospitalized Cases Tied to Kobayashi Pharma’s Supplements Now Up to 26
March 26, 2024
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…